DURHAM, N.C., and BEIJING, China – December 21, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conferences in January 2023. Details of the conferences are as follows:

Morgan Stanley Virtual China Opportunity Conference

Meeting Date: January 4-6, 2023

Participants: Management team and IR

For more information, please contact your Morgan Stanley representative.

BIO Partnering @ JPM (in-person and virtual)

Meeting Date: January 9-12, 2023

Meeting Location: San Francisco Marriott Marquis

Participants: Management team

For one-on-one meeting request, please visit the event website.

UBS Great China Conference 2023 (in-person and virtual)

Meeting Date: January 9-13, 2023

Participants: Management team and IR

For more information, please contact your UBS representative.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens worldwide. For more information, visit www.briibio.com.

Media Inquiry:
media@briibio.com
Darcie Robinson (U.S.)
+1-203-919-7905

Investor Inquiry:
ir@briibio.com